anastrozole
anastrozole: developed by 1 company · 33 clinical trials tracked · 1 FDA decision.
anastrozole evidence translation
What we can confirm
1 FDA record · 33 tracked trials
What it means
What to watch
Prepared research question
How could anastrozole → AZN affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 12 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| ASTRAZENECA PLC (AZN) Hormone Receptor Positive Breast Cancer | Phase 3 |
Clinical Trials (33)showing 10 most recent
A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer With RS</=25 (RxFINE-Low)
Primary endpoint: Invasive breast cancer-free survival (iBCFS)
Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice
Primary endpoint: Number (%) of patients who remain on treatment with ribociclib + AI over the 12 months period
A Phase 2, Randomized, Open-Label Dose Optimization and Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY4064809 Combined With a CDK4/6 Inhibitor and Endocrine Therapy in Adults With HR+, HER2-Advanced Breast Cancer With a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2)
Primary endpoint: (Part 1): Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR)
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
Primary endpoint: Invasive breast cancer-free survival (IBCFS) according to the Standardized Definitions for Efficacy End Points (STEEP) criteria in a prospective cohort
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients With Molecular Low-Risk Early-Stage Breast Cancer
Primary endpoint: Recurrence-free interval (RFI)
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study
Primary endpoint: Invasive Breast Cancer-Free Survival (IBCFS)
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients With BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
Primary endpoint: Progression-Free Survival (Arm 1 vs arm 2)
A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator's Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301)
Primary endpoint: Progression Free Survival (PFS) per blinded independent central review (BICR)
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse
Primary endpoint: Distant metastasis free survival (DMFS)
A Phase 3 Randomized, Open-Label Study of OP-1250 Monotherapy vs Standard of Care for the Treatment of ER+, HER2- Advanced or Metastatic Breast Cancer Following Endocrine and CDK 4/6 Inhibitor Therapy (OPERA-01)
Primary endpoint: Dose-Selection Part: Incidence of adverse events
FDA Decisions1 records
Frequently asked questions
Who is developing anastrozole?
anastrozole is being developed by ASTRAZENECA PLC.
How many clinical trials involve anastrozole?
BioSniper tracks 33 clinical trials involving anastrozole.
What is anastrozole's latest FDA decision?
The most recent tracked FDA decision for anastrozole is Approval for 1 INDICATIONS AND USAGE ARIMIDEX is an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer ( 1.2 ) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients , dated December 5, 2008.